Want to see CH:BION full AI Analyst Report?
Total Valuation
BB Biotech has a market cap or net worth of CHF2.79B. The enterprise value is -CHF387.73.
Market CapCHF2.79B
Enterprise Value-CHF387.73
Share Statistics
BB Biotech has 55,149,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding55,149,250
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BB Biotech’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 21.06%.
Return on Equity (ROE)0.21
Return on Assets (ROA)0.21
Return on Invested Capital (ROIC)21.06%
Return on Capital Employed (ROCE)0.21
Revenue Per Employee7.68M
Profits Per Employee0.00
Employee Count10
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BB Biotech is 2.1. BB Biotech’s PEG ratio is 0.00642.
PE Ratio2.1
PS Ratio32.10
PB Ratio0.89
Price to Fair Value0.89
Price to FCF7.97
Price to Operating Cash Flow9.25
PEG Ratio0.00642
Income Statement
In the last 12 months, BB Biotech had revenue of 76.81M and earned 578.13M in profits. Earnings per share was 10.54.
Revenue76.81M
Gross Profit76.76M
Operating Income586.83M
Pretax Income578.20M
Net Income578.13M
EBITDA578.64M
Earnings Per Share (EPS)10.54
Cash Flow
In the last 12 months, operating cash flow was 302.78M and capital expenditures 0.00, giving a free cash flow of 302.78M billion.
Operating Cash Flow302.78M
Free Cash Flow302.78M
Free Cash Flow per Share5.49
Dividends & Yields
BB Biotech pays an annual dividend of CHF2.25, resulting in a dividend yield of 4.4%
Dividend Per ShareCHF2.25
Dividend Yield4.4%
Payout Ratio9.18%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.93
52-Week Price Change67.55%
50-Day Moving Average47.44
200-Day Moving Average44.18
Relative Strength Index (RSI)56.56
Average Volume (3m)98.23K
Important Dates
BB Biotech upcoming earnings date is Oct 23, 2026, Before Open (Confirmed).
Last Earnings DateJul 24, 2026
Next Earnings DateOct 23, 2026
Ex-Dividend Date―
Financial Position
BB Biotech as a current ratio of 0.00, with Debt / Equity ratio of 0.00%
Current Ratio0.00
Quick Ratio0.00
Debt to Market Cap0.00
Net Debt to EBITDA-0.17
Interest Coverage Ratio1.32K
Taxes
In the past 12 months, BB Biotech has paid 66.00K in taxes.
Income Tax66.00K
Effective Tax Rate<0.01
Enterprise Valuation
BB Biotech EV to EBITDA ratio is 4.09, with an EV/FCF ratio of 7.66.
EV to Sales30.82
EV to EBITDA4.09
EV to Free Cash Flow7.66
EV to Operating Cash Flow7.66
Balance Sheet
BB Biotech has CHF3.08B in cash and marketable securities with CHF0.00 in debt, giving a net cash position of CHF3.08B billion.
Cash & Marketable SecuritiesCHF3.08B
Total DebtCHF0.00
Net CashCHF3.08B
Net Cash Per ShareCHF55.78
Tangible Book Value Per ShareCHF50.67
Margins
Gross margin is 100.00%, with operating margin of 763.99%, and net profit margin of 752.66%.
Gross Margin100.00%
Operating Margin763.99%
Pretax Margin752.75%
Net Profit Margin752.66%
EBITDA Margin753.32%
EBIT Margin753.32%
Analyst Forecast
The average price target for BB Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast45.59%
EPS Growth Forecast―